New Pancreatic Cancer Pill Shrinks Tumors by 76%

A daily pill could finally offer hope to people facing pancreatic cancer, a disease so deadly that only 13% of patients survive five years after diagnosis.

Revolution Medicines is about to release results from a Phase 3 trial of daraxonrasib, which could become the first targeted treatment for pancreatic cancer. The drug goes straight to the source, attacking RAS mutations found in 90% of pancreatic cancer cases.

Former Republican Senator Ben Sasse brought national attention to the treatment this week when he shared his own story with The New York Times. Diagnosed with Stage 4 pancreatic cancer last year and given just three to four months to live, Sasse has seen his tumors shrink by 76% since starting the medication.

The drug works differently than anything before it. Instead of just managing symptoms, daraxonrasib targets the mutations that actually drive tumor growth. RBC Capital Markets analyst Leonid Timashev calls it "potentially the biggest breakthrough in pancreatic cancer ever."

Getting to this point wasn't easy. Revolution Medicines CEO Mark Goldsmith remembers his team holding their heads in their hands during early dose testing, worried each increase might be too much for patients to handle. They started with extremely low doses and climbed carefully, unsure if people could even tolerate such a broadly active drug.

The scientists predicted tumors would shrink at 80 milligrams. When the first patient's tumor actually shrank at that exact dose, the team knew they had something special.

The treatment does come with side effects. Because RAS proteins exist throughout the body, especially in skin, the drug causes rashes in many patients. Sasse described the medication as "nasty" with "crazy" side effects that left his face bloody and peeling. But Revolution Medicines reports most rashes are low grade, and no patients have stopped treatment because of them.

Why This Inspires

Pancreatic cancer survival rates have barely budged while other cancers saw major improvements from new treatments like immunotherapy. This drug represents the first real shift in decades for patients who desperately need options.

The company expects to share full Phase 3 trial data this quarter, comparing the pill against chemotherapy in patients whose cancer has spread. To win FDA approval, Revolution Medicines needs to prove the drug keeps people alive longer, not just shrink tumors.

If successful, daraxonrasib could help the 66,000 Americans diagnosed with pancreatic cancer each year. Revolution Medicines has focused on building something that makes a real difference, even as bigger pharmaceutical companies circle with acquisition interest.

The breakthrough shows what happens when scientists refuse to give up on the toughest medical challenges.